Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate for ankylosing spondylitis.

J Chen1, C Liu

  • 1Australasian Cochrane Centre, Level 1, Block E, Locked Bag 29, Monash Medical Centre, Clayton, Melbourne, Vitoria, Australia, 3168. drjunminchen@hotmail.com

The Cochrane Database of Systematic Reviews
|July 22, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of acupuncture and moxibustion for keeping shape.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·1999
Same author

Two-effective-source method for the calculation of in-air output at various source-to-detector distances in wedged fields.

Medical physics·1999
Same author

Follow up of women with simple ovarian cysts detected by transvaginal sonography in the Tokyo metropolitan area.

British journal of obstetrics and gynaecology·1999
Same author

(R)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionamides are orally active inhibitors of pyruvate dehydrogenase kinase.

Journal of medicinal chemistry·1999
Same author

Expression analysis of multidrug resistance associated genes in neuroblastomas.

Oncology reports·1999
Same author

A random survey of the Cryptosporidium parvum genome.

Infection and immunity·1999

Methotrexate (MTX) did not show significant benefits for ankylosing spondylitis (AS) patients in reviewed trials. Further high-quality, larger studies are needed to confirm MTX efficacy and safety in AS treatment.

Area of Science:

  • Rheumatology
  • Clinical Immunology
  • Pharmacology

Background:

  • Ankylosing spondylitis (AS) is a chronic inflammatory condition affecting the spine.
  • Current treatments primarily manage symptoms with NSAIDs, with limited options for refractory cases.
  • Methotrexate (MTX), a disease-modifying antirheumatic drug (DMARD), is widely used for rheumatoid arthritis but its role in AS is uncertain.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of methotrexate (MTX) in treating ankylosing spondylitis (AS).

Main Methods:

  • Systematic review of randomized and quasi-randomized trials sourced from CENTRAL, MEDLINE, EMBASE, and CINAHL.
  • Independent review of trial reports, quality assessment, and data extraction by two reviewers.
  • Meta-analysis using weighted/standardized mean differences or relative risks where heterogeneity allowed.

Related Experiment Videos

Main Results:

  • Two trials involving 81 patients compared MTX (7.5-10 mg/week) with placebo or naproxen alone.
  • No statistically significant differences were observed in outcomes such as function, pain, or inflammatory markers (CRP, ESR) favoring MTX.
  • No serious adverse events were reported in the included studies.

Conclusions:

  • Methotrexate (MTX) demonstrated no statistically significant benefit for ankylosing spondylitis (AS) patients in the evaluated outcomes.
  • High-quality, larger, and longer randomized controlled trials, potentially using higher MTX dosages, are required to clarify its efficacy and toxicity in AS.